Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal
Review of OncoVAX®
October 22, 2009
Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
July 24, 2009
Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal Review of OncoVAX®
July 17, 2009
May 15, 2009
April 20, 2009
Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the Barcelona Vaccine Forum 2009 in June 2009
March 1, 2009
Vaccinogen Announces Addition of David Hatt to its Board of Directors
November 14, 2008
November 13, 2008
OncoVAX, Other Vaccines Provide Hope for Colorectal Cancer Treatment, Prevention
June 4, 2008
Thomson Reuters' Pharma Matters highlights Vaccinogen’s OncoVAX® as “One to Watch”
May 7, 2008
February 27, 2008
Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year
February 11, 2008
Cancer Pioneer Reaches Key Agreement On Colon Cancer Drug OncoVAX®
November 10, 2007
Vaccinogen Announces the Successful Acquisition of Key Management and Staff
November 4, 2007
Vaccinogen Announces Successful Acquisition of cGMP Manufacturing Facility
November 3, 2007
Vaccinogen Announces Completion of its Initial Capitalization Plan
October 1, 2007
Vaccinogen Announces Formation of Company
July 19, 2006
FDA Grants Special Protocol Assessment
July, 2006
FDA Grants Intracel “Fast Track ” Designation for the Development of Its Colon Cancer Vaccine
Frederick, MD, USA – July 24, 2009 – Vaccinogen, Inc. announces that it has submitted its final documentation to Swissmedic for pivotal review of OncoVAX®. Swissmedic is expected to issue final decision to approve full registration thus Swiss reimbursement for OncoVAX® by the end of 2009.
OncoVAX® currently has a marketing authorization from Swissmedic, Switzerland’s medical authority, in the category of “procedes therapeutiques”. This authorization permits foreign and domestic Swiss patients to purchase OncoVAX® on a self-pay basis. During this period, Swissmedic required Vaccinogen to apply for full registration of OncoVAX® as a transplant therapy. A final positive decision will permit Vaccinogen to apply for insurance reimbursement within Switzerland.
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
Vaccinogen’s scientists prepare a vaccine from the patient’s own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth “booster” is administered six months later. OncoVAX® reduces recurrence and deaths by over 50%.
About Vaccinogen
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, antiinflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX® vaccines.
About Swissmedic
Swissmedic, the Swiss agency for therapeutic products, is the Swiss surveillance authority for medicines and medical devices, registered in Berne. It started operations on January 1, 2002 as successor of Interkantonale Kontrollstelle fur Heilmittl (IKS), which was itself the successor of Schweizerische Arzeimittelnebenwirkugszentrale (SANZ). Swissmedic is affiliated to the Federal department of Home Affairs.
Contact:
Andrew L. Tussing
Vaccinogen
atussing@vaccinogeninc.com
301-668-8400